Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study

Launched by ZHEJIANG UNIVERSITY · Dec 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 99mTc-FDPH46 SPECT/CT to see how well it can help doctors diagnose malignant solid tumors, which are types of cancer that form solid masses. The researchers want to find out if this method is as accurate as the current standard tests used to confirm cancer. They will also look at how the imaging agent behaves in the body, how it is absorbed by tumors, and whether it is safe for patients to use.

To participate in this trial, patients should be between 18 and 80 years old and have been diagnosed with or are suspected of having a malignant solid tumor. They should also be in stable health and able to handle the test. If you join the study, you will undergo the 99mTc-FDPH46 SPECT/CT examination after signing a consent form, which means you agree to participate. This trial is not yet recruiting participants, but it's an important step in finding better ways to diagnose and treat cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who are clinically suspected or diagnosed with malignant solid tumors.
• • 2. Ages between 18 to 80 years old.
• • 3. Stable vital signs, ECOG score of 0-2, capable of tolerating and cooperating with the 99mTc-FDPH46 SPECT/CT examination.
• • 4. Subjects who are willing to undergo the 99mTc-FDPH46 SPECT/CT examination and have signed the informed consent form.
• Exclusion Criteria:
• • 1. Those who can not understand, comply with the research protocol or are unable to sign the informed consent form.
• • 2. Contraindications for SPECT imaging (including pregnant women, nursing women, women of childbearing age with recent plans to conceive, etc.).
• • 3. Unstable vital signs, ECOG score \>2, unable to tolerate or cooperate with the 99mTc-FDPH46 SPECT/CT examination process.